Companies / TScan Therapeutics, Inc.

TScan Therapeutics, Inc.

Nasdaq: TCRXCIK 1783328WALTHAM, MA

Financials · FY2025

Revenue$10.32M
Net income$-129.77M
Total debt$32.78M
Cash$100.16M
Diluted EPS$-1.00
Shares outstanding67.8M

Ownership

67.8M shares outstanding · as of Aug 7, 2026
47.9%Institutions
Ownership
93.7%Common Stock
Share classes
Common Stock93.69%
Common Stock6.31%
Institutions47.92%32,476,972
Public float52.08%35,302,283

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 11

View all →
Insider% of sharesShares
667, L.P.Director
Amello JasonChief Financial Officer
Baker FelixDirector
Baker JulianDirector
Dworak LeidenSee Remarks
Louis ChrystalChief Medical Officer
MacBeath GavinCEOChief Executive Officer · Director

Institutional holders 62

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
May 20, 2026Baker Bros. Advisors LP
Director
GrantNon- Qualified Stock Option (right to buy)+67K
67,000
0.10% of shares
low
May 20, 2026Baker Bros. Advisors LP
Director
GrantNon- Qualified Stock Option (right to buy)+67K
67,000
0.10% of shares
low
Jan 20, 2026Amello Jason
Executive
GrantStock Option (Right to Buy)+350K
350,000
0.52% of shares
low
Jan 20, 2026MacBeath Gavin
CEO
GrantStock Option (Right to Buy)+1.2M
1,165,000
1.72% of shares
low
Jan 20, 2026Dworak Leiden
Executive
GrantStock Option (Right to Buy)+100K
100,000
0.15% of shares
low
Jan 20, 2026Louis Chrystal
Executive
GrantStock Option (Right to Buy)+420K
420,000
0.62% of shares
low
Jan 20, 2026Zdraveski Zoran
Executive
GrantStock Option (Right to Buy)+350K
350,000
0.52% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
TCRXCommon StockEquity89854M101BBG00PH1N007